Back to top
more

Repligen (RGEN)

(Real Time Quote from BATS)

$160.98 USD

160.98
408,369

-0.69 (-0.43%)

Updated Aug 5, 2024 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Will Repligen (RGEN) Gain on Rising Earnings Estimates?

Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.

Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y

Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.

Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat

Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.

Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.

Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline

Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.

Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up

Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.

CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y

CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.

BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance

BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.

Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow

Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.

Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021. Resultantly, the stock rises.

Company News for Jul 28, 2021

Companies In The News Are: RGEN, SIRI, BSX, FISV.

Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

Repligen (RGEN) Q2 Earnings and Revenues Surpass Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 49.06% and 12.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study

Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.

Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study

Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.

AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe

AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.

Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H

Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.